Bionano Genomics

Digital Pathology Transition Will Advance Precision Medicine Adoption

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

16 Apr 25

Updated

09 Dec 25

Views

73

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

-87.4%

7D

0.7%

Loading

1Y

-87.4%

7D

0.7%

You can edit this narrative until Dec 10 3:10 PM. Then, changes will post as Updates.

Author's Valuation

US$7.579.6% undervalued

AnalystConsensusTarget Fair Value

Shared on 09 Dec 25

BNGO: Clinical Study Momentum Will Drive Stronger Demand And Upside Through 2025

Analysts have modestly reiterated their outlook on Bionano Genomics, keeping the price target effectively unchanged as incremental tweaks to the discount rate, revenue growth, and margin assumptions suggest a steady, but not markedly altered, risk reward profile. What's in the News Bionano Genomics issued new revenue guidance for fourth quarter 2025, targeting $7.5 million to $7.9 million, while reiterating full year 2025 revenue expectations of $26.0 million to $30.0 million (company guidance filing).

Shared on 25 Nov 25

Fair value Decreased 21%

BNGO: Clinical Study Results Will Drive Increased Demand Through 2025

Analysts have lowered their price target for Bionano Genomics from $9.50 to $7.50 per share, citing updated forecasts for valuation and growth. What's in the News Bionano Genomics initiated earnings guidance for the fourth quarter of 2025, projecting revenue between $7.5 million and $7.9 million, and reiterated full-year 2025 revenue guidance of $26.0 million to $30.0 million (company guidance).

Shared on 15 Aug 25

Fair value Increased 5.56%

With both the consensus price target and future P/E holding steady, no notable valuation shift is apparent for Bionano Genomics, keeping fair value unchanged at $9.00. What's in the News Peer-reviewed study demonstrated Bionano's optical genome mapping (OGM) detects novel oncogenic structural variants in infant/toddler T-cell acute lymphoblastic leukemia missed by conventional cytogenetics, identifying distinct prognostic subgroups.

Shared on 01 May 25

Fair value Increased 91%

Shared on 24 Apr 25

Fair value Decreased 36%

AnalystConsensusTarget has decreased revenue growth from 25.2% to 4.2%, increased future PE multiple from 5.0x to 6.5x, increased discount rate from 9.8% to 11.4% and decreased shares outstanding growth rate from 0.3% to 0.1%.

AnalystConsensusTarget Fair Value

US$7.5

79.6% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

25.00%

Life Sciences revenue growth rate

0.26%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

10.27%

Calculation

US$17.95m

Earnings '28

x

12.45x

PE Ratio '28

=

US$223.44m

Market Cap '28

US$223.44m

Market Cap '28

/

22.36m

No. shares '28

=

US$9.99

Share Price '28

US$9.99 Share Price '28

Discounted to 2025 @ 10.04% p.a.

=

US$7.50

Fair Value '25